3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
144
Neoplasms
130
Prostatic Neoplasms
81
Carcinoma, Non-Small-Cell Lung
79
Lung Neoplasms
65
Colorectal Neoplasms
46
Carcinoma, Hepatocellular
37
Stomach Neoplasms
33
Multiple Myeloma
28
Brain Neoplasms
28
Uterine Cervical Neoplasms
27
Melanoma
26
Pancreatic Neoplasms
25
Rectal Neoplasms
24
Ovarian Neoplasms
24
Head and Neck Neoplasms
23
Colonic Neoplasms
23
Urinary Bladder Neoplasms
22
Hematologic Neoplasms
22
Neoplasm Metastasis
21
Esophageal Neoplasms
20
Carcinoma, Renal Cell
20
Leukemia, Myeloid, Acute
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Endometrial Neoplasms
17
Recurrence
15
Cardiovascular Diseases
15
Thyroid Neoplasms
14
Lymphoma
14
Liver Neoplasms
14
Interventions
enzalutamide
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Observational
×
Metastatic Hormone-sensitive Prostate Cancer
×
Clear all
NCT05901649
2026-06-05
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
504 enrolled
NCT06874114
2026-04-13
RE-ENGAGE
Bayer
Active not recruiting
700 enrolled